(PR-inside.com) NEW YORK, NY -- (Marketwire) -- 04/04/11 -- Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million.Lexiscan (regadenoson) is a market-leading pharmacologic stress agent (PSA) for radionuclide myocardial perfusion imaging (MPI) -- a test that detects and characterizes coronary artery disease -- in patients unable to undergo adequate exercise stress. Lexiscan, which was co-developed by CV Therapeutics (now Gilead) and Astellas, is the first A2A adenosine receptor agonist shown to be safe and effective as a pharmacologic ..
More...
More...